TCR2 Therapeutics
675 West Kendall Street
Suite I
Cambridge
Massachusetts
02142
United States
Tel: 617-475-8469
Website: http://www.tcr2.com/
Email: info@tcr2.com
About TCR2 Therapeutics
At TCR2 Therapeutics we have a bold vision – to cure cancer by using our immune system in a more natural way. We have developed a unique proprietary TRuC™ platform based on T cell receptor fusion constructs that have the advantage of employing the full signaling power inherent to a complete T cell receptor (TCR). Our TRuC™ variants can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. We have demonstrated activity against both hematological and solid tumor targets in preclinical models and we believe TRuC™-T cells will serve as the engine for novel therapies which we are quickly advancing towards the clinic.The company was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. We have since assembled a world class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA.
YEAR FOUNDED:
2015
LEADERSHIP:
Founder: Dr. Patrick Baeuerle
CEO: Garry Menzel, PhD and MBA
CSO: Robert Hofmeister, PhD
Acting CSO: John Pallies
Chief IP Counsel: Gregory Sieczkiewicz, PhD and JD
Head of Corporate Development: Helen Ho, PhD
Manager of Human Reources & Office Dynamics: Eva Quinn
TECHNOLOGY:
Please click here for TCR2 Therapeutics's technology.
116 articles about TCR2 Therapeutics
-
TCR2 Therapeutics Announces Exercise of Over-Allotment Option
2/26/2019
TCR2 Therapeutics Inc. announced that the underwriters of its recent initial public offering of common stock have exercised in full their over-allotment option and purchased an additional 750,000 shares at $15.00 per share, before deducting underwriting discounts and commissions.
-
TCR2 Therapeutics Announces Pricing of Initial Public Offering of Common Stock
2/14/2019
TCR2 Therapeutics Inc. announced the pricing of the Company's initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share, for aggregate gross proceeds of $75.0 million, before deducting underwriting discounts and commissions and offering expenses.
-
TCR2 Therapeutics Launches Proposed Initial Public Offering
2/1/2019
TCR2 Therapeutics Inc. announced that it has launched an underwritten initial public offering of 5,000,000 shares of its common stock at an initial public offering price expected to be between $14.00 and $16.00 per share.
-
Cambridge, Mass.-based TCR2 Therapeutics is looking to secure $100 million in an initial public offering. Just before the end of 2018, the company filed its prospectus with the U.S. Securities and Exchange Commission, hoping that the new year will continue the IPO frenzy biotech enjoyed for much ...
-
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
-
TCR2 Therapeutics wins U.S. Private Company of the Year Award at LifeStars Awards™ Life Sciences 2018 Event
11/29/2018
Recognition for pioneering new approaches in T cell immunotherapy
-
TCR2 Therapeutics to Present at the UBS Global Healthcare Conference and the Jefferies 2018 Global Healthcare Conference
5/14/2018
TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today that its Chief Executive Officer, Garry E. Menzel, PhD, will present a corporate overview at the following upcoming investment conferences
-
TCR2 Therapeutics to Present New Preclinical Data at the American Association for Cancer Research (AACR) 2018 Annual Meeting
4/12/2018
TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today that new preclinical data on its TRuC™ platform and its lead solid tumor program TC-210 will be presented at the American Association for Cancer Research (AACR) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, IL.
-
TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer
4/10/2018
TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today the appointment of Ian Somaiya as Chief Financial Officer.
-
TCR2 Therapeutics has raised $125 million in Series B financing to advance two T-Cell receptor (TCR) programs through clinical proof-of-concept.
-
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing
3/21/2018
Proceeds will support clinical development of lead program TC-210 and expansion of the multi-format TRuC™-T cell pipeline in solid tumors and blood cancers
-
TCR2 Therapeutics Appoints Cell Therapy Pioneer Dr. Stephan Grupp to Advisory Board
11/2/2017
"Dr. Stephan Grupp has helped to revolutionize T cell immunotherapy and we are thrilled to welcome him to TCR2's Advisory Board," said Mitchell Finer, PhD, Chairman of TCR2's Advisory Board and Member of the company's Board of Directors.
-
TCR2 Therapeutics Appoints Leading Cell Therapy Expert As Chief Medical Officer
10/12/2017
-
TCR2 Therapeutics To Present Solid Tumor Data At CAR-TCR Summit And CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
8/29/2017
-
TCR2 Therapeutics Presents Positive Solid Tumor Data For Its Novel TRuC Engineered T Cell Therapies At The World Preclinical Congress
6/13/2017
-
Cambridge Biotech TCR2 Therapeutics Launches From Stealth Mode With $44.5 Million
12/8/2016